ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,572.85
      0.10%
      US Tech 100
      19,968.40
      0.38%
      Dow Jones
      39,344.79
      -0.08%
      Brent Oil
      85.115
      -0.35%
      Bitcoin
      57,463.13
      1.35%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vanda Pharmaceuticals Inc (VNDA)

      7. Vanda Pharmaceuticals Inc (VNDA) News

      VNDA

      Vanda Pharmaceuticals (VNDA)

      Vanda Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VNDA
      DateTimeSourceHeadlineSymbolCompany
      04/17/20249:02AMPR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
      04/03/202410:25AMAllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
      04/02/20246:10PMPR Newswire (US)Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I DisorderNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/07/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/06/20244:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/06/20244:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/06/20244:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/06/20244:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/06/20244:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/06/20247:00AMPR Newswire (US)Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/04/20249:14PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/04/20249:12PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/04/20249:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/04/20249:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      03/04/20249:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/21/20244:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/21/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/21/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/21/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/21/20244:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/21/20244:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/16/20244:31PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
      02/08/20247:19AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VNDAVanda Pharmaceuticals Inc
      02/07/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/07/20244:02PMPR Newswire (US)Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/05/20244:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
      02/05/20248:00AMPR Newswire (US)Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaNASDAQ:VNDAVanda Pharmaceuticals Inc
      01/31/20244:30PMPR Newswire (US)Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
      01/31/20249:00AMPR Newswire (US)Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of OnychomycosisNASDAQ:VNDAVanda Pharmaceuticals Inc
      01/30/202412:35PMPR Newswire (US)Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:VNDA